Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Operating Leases (2019 - 2025)

Syndax Pharmaceuticals (SNDX) has disclosed Operating Leases for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For Q4 2025, Operating Leases fell 3.61% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 3.61%, while the annual FY2025 figure was $1.5 million, 3.61% down from the prior year.
  • Operating Leases hit $1.5 million in Q4 2025 for Syndax Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $1.6 million in Q4 2024 and bottomed at $22000.0 in Q2 2021.
  • Average Operating Leases over 5 years is $685750.0, with a median of $676000.0 recorded in 2022.
  • Year-over-year, Operating Leases plummeted 90.83% in 2021 and then surged 2490.91% in 2022.
  • Syndax Pharmaceuticals' Operating Leases stood at $711000.0 in 2021, then dropped by 0.28% to $709000.0 in 2022, then dropped by 18.48% to $578000.0 in 2023, then soared by 173.01% to $1.6 million in 2024, then dropped by 3.61% to $1.5 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $1.5 million, $1.6 million, and $133000.0 for Q4 2025, Q4 2024, and Q2 2024 respectively.